Logotype for Koninklijke Ahold Delhaize N.V.

Koninklijke Ahold Delhaize (AD) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Koninklijke Ahold Delhaize N.V.

Q2 2026 earnings summary

5 Aug, 2026

Executive summary

  • Delivered resilient Q2 2026 performance with net sales up 1.9% at constant rates to €23.2 billion, gaining market share across major markets and brands despite a challenging macroeconomic environment.

  • Strong execution of the Growing Together strategy, marking the 10th anniversary of the Ahold and Delhaize merger.

  • Focused on customer value, Own Brand expansion, disciplined investment, and technology-driven efficiency.

  • Online sales surged 8.6% at constant rates, led by 14.5% growth in the U.S., reflecting strong omnichannel execution.

  • Underlying operating margin was 3.9%, down 0.1 percentage points, with improvements in Europe offset by a modest U.S. decline.

Financial highlights

  • Q2 net sales reached €23.2 billion (+1.9% constant rates, +0.3% actual rates), with a 10 basis point negative impact from calendar shifts.

  • Underlying operating income was €906 million (+0.3% constant rates); underlying operating margin was 3.9%, down 0.1 pts.

  • Q2 diluted underlying EPS was €0.63, down 1.4% at constant rates; IFRS operating income was €866 million.

  • Q2 free cash flow was €632 million; year-to-date free cash flow €302 million, impacted by working capital timing.

  • Online sales grew 8.6% at constant rates to €2.7 billion.

Outlook and guidance

  • Reiterated 2026 outlook: underlying operating margin around 4%, mid- to high-single-digit EPS growth at constant rates, free cash flow at least €2.3 billion, and gross capital expenditures around €2.7 billion.

  • 2026 will have a 53rd week, expected to boost net sales by 1.5-2% and underlying income by 2-3%.

  • Commitment to share buyback and dividend programs, with a targeted dividend payout ratio of 40-50%.

  • Expect continued dynamic and demanding operating environment, with subdued volumes and high competition.

  • Inflation Reduction Act to negatively impact U.S. pharmacy sales by ~$450 million, with no material effect on underlying operating income.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more